High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Baraka, Vito ^a,b   Ishengoma, Deus S ^a   Fransis, Filbert ^a   Minja, Daniel T R ^a   Madebe, Rashid A ^a   Ngatunga, Deogratius ^c   Van Geertruyden, Jean Pierre ^b  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Tanzania Food and Drugs Authority   (Tanzania)

Author keywords

Molecular markers; Pfdhps; Plasmodium falciparum; Septuple Pfdhfr; Single nucleotide polymorphisms; Sulphadoxine pyrimethamine; Tanzania

Indexed keywords

DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; GENOMIC DNA; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; BIOLOGICAL MARKER; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PROTOZOAL PROTEIN; PYRIMETHAMINE; SULFADOXINE;

ADULT; AGED; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DHFR GENE; DHPS GENE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HAPLOTYPE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; NONHUMAN; PARASITOLOGY; PATHOGENESIS; PLASMODIUM FALCIPARUM; PREGNANCY OUTCOME; SEQUENCE SPECIFIC OLIGONUCLEOTIDE PROBE; SINGLE NUCLEOTIDE POLYMORPHISM; TANZANIA; TREATMENT WITHDRAWAL; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; MUTATION; POLYMERASE CHAIN REACTION; TIME FACTOR;

ANTIMALARIALS; BIOMARKERS; CROSS-SECTIONAL STUDIES; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HAPLOTYPES; MUTATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PROTOZOAN PROTEINS; PYRIMETHAMINE; SULFADOXINE; TANZANIA; TETRAHYDROFOLATE DEHYDROGENASE; TIME FACTORS;

EID: 84960091839     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0977-8     Document Type: Article

References (52)

1. Griffin JT, Ferguson NM, Ghani AC. Estimates of the changing age-burden of Plasmodium falciparum malaria disease in sub-Saharan Africa. Nat Commun. 2014;5:3136.
2. Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, et al. Artemisinin resistance: Current status and scenarios for containment. Nat Rev Microbiol. 2010;8:272-80.
3. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50-5.
4. Mugittu K, Abdulla S, Falk N, Masanja H, Felger I, Mshinda H, et al. Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: Assessment protocol and implication for treatment policy strategies. Malar J. 2005;4:55.
5. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis. 2002;2:209-18.
6. Wellems TE, Plowe CV. Chloroquine-Resistant Malaria. J Infect Dis. 2001;184:770-6.
7. WHO. Guideline for the treatment of malaria. 2nd edn. Geneva: World Health Organization; 2010.
8. Policy M, Committee A. Malaria Policy Advisory Committee to the WHO: Conclusions and recommendations of March 2013 meeting. Malar J. 2013;12:213.
9. WHO. Seasonal Malaria Chemoprevention (SMC) for Plasmodium falciparum control in highly seasonal transmission areas of Sahel sub-region in Africa. Geneva. World Health Organization, 2012.
10. Mulligan JA, Mandike R, Palmer N, Williams H, Abdulla S, Bloland P, et al. The costs of changing national policy: Lessons from malaria treatment policy guidelines in Tanzania. Trop Med Int Health. 2006;11:452-61.
11. Mugittu K. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy. Trop Med Int Health. 2007;12:219-23.
12. Mugittu K, Genton B, Mshinda H, Beck HP. Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania. Malar J. 2006;5:126.
13. Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: Dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem. 1994;224:397-405.
14. Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA. 1997;94:13944-9.
15. Lynch C, Pearce R, Pota H, Cox J, Abeku TA, Rwakimari J, et al. Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. J Infect Dis. 2008;197:1598-604.
16. McCollum AM, Poe AC, Hamel M, Huber C, Zhou Z, Shi YP, et al. Antifolate resistance in Plasmodium falciparum: Multiple origins and identification of novel dhfr alleles. J Infect Dis. 2006;194:189-97.
17. Minja DTR, Schmiegelow C, Mmbando B, Boström S, Oesterholt M, Magistrado P, et al. Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight. Tanzania. Emerg Infect Dis. 2013;19:1446-54.
18. Harrington WE, Morrison R, Fried M, Duffy PE. Intermittent preventive treatment in pregnant women is associated with increased risk of severe malaria in their offspring. PLoS ONE. 2013;8:e56183.
19. Naidoo I, Roper C. Mapping "partially resistant", "fully resistant", and "super resistant" malaria. Trends Parasitol. 2013;29:505-15.
20. McCollum AM, Mueller K, Villegas L, Udhayakumar V, Escalante AA. Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrob Agents Chemother. 2007;51:2085-91.
21. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380-8.
22. Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J. 1998;17:3807-15.
23. Vinayak S, Alam MT, Mixson-Hayden T, McCollum AM, Sem R, Shah NK, Lim P, Muth S, Rogers WO, Fandeur T, Barnwell JW, Escalante AA, Wongsrichanalai C, Ariey F, Meshnick SR, Udhayakumar V. Origin and evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog. 2010;6:e1000830.
24. Matondo SI, Temba GS, Kavishe AA, Kauki JS, Kalinga A, Van Zwetselaar M, Reyburn H, Kavishe RA. High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: A cross sectional survey of six regions in Tanzania. Malar J. 2014;13:1-7.
25. Juma DW, Omondi AA, Ingasia L, Opot B, Cheruiyot A, Yeda R, et al. Trends in drug resistance codons in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Kenyan parasites from 2008 to 2012. Malar J. 2014;13:250.
26. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, et al. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at codon 581. PLoS ONE. 2009;4:e4569.
27. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis. 2011;53:224-30.
28. WHO. WHO Evidence Review Group on Intermittent Preventive Treatment (IPT) of malaria in pregnancy, Geneva. World Health Organization, 2013.
29. WHO. WHO Policy Brief for the Implementation of Intermittent Preventive Treatment of Malaria in Pregnancy.,Geneva. World Health Organization, 2013.
30. National Bureau of Statistics. 2011-2012 Tanzania HIV/AIDS and Malaria Indicator Survey. Dar es Salaam: NBS; 2012.
31. MoHSW. National Guidelines for malaria diagnosis and treatment. Ministry of Health: United Republic of Tanzania; 2006.
32. Shayo A, Mandara CI, Shahada F, Buza J, Lemnge MM, Ishengoma DS. Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania. Malar J. 2014;13:376.
33. Venkatesan M, Amaratunga C, Campino S, Auburn S, Koch O, Lim P, et al. Using CF11 cellulose columns to inexpensively and effectively remove human DNA from Plasmodium falciparum-infected whole blood samples. Malar J. 2012;11:41.
34. Alifrangis M, Enosse S, Pearce R, Drakeley C, Roper C, Khalil IF, et al. A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction-and enzy. Am J Trop Med Hyg. 2005;72:155-62.
35. Pearce RJ, Drakeley C, Chandramohan D, Mosha F, Roper C. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of Northern Tanzania. Antimicrob Agents Chemother. 2003;47:1347-54.
36. Alifrangis M, Lusingu JP, Mmbando B, Dalgaard MB, Vestergaard LS, Ishengoma D, et al. Five-Year Surveillance of Molecular Markers of Plasmodium falciparum Antimalarial Drug Resistance in Korogwe District, Tanzania: Accumulation of the 581G Mutation in the P. falciparum Dihydropteroate Synthase Gene. Am J Trop Med Hyg. 2009;80:523-7.
37. Alifrangis M, Nag S, Schousboe ML, Ishengoma D, Lusingu J, Pota H, et al. Independent origin of plasmodium falciparum antifolate super-resistance, Uganda, Tanzania, and Ethiopia. Emerg Infect Dis. 2014;20:1280-6.
38. Malisa AL, Pearce RJ, Abdulla S, Mshinda H, Kachur PS, Bloland P, et al. Drug coverage in treatment of malaria and the consequences for resistance evolution-evidence from the use of sulphadoxine/pyrimethamine. Malar J. 2010;9:190.
39. Ishengoma DS, Mmbando BP, Segeja MD, Alifrangis M, Lemnge MM, Bygbjerg IC. Declining burden of malaria over two decades in a rural community of Muheza district, north-eastern Tanzania. Malar J. 2013;12:338.
40. Mmbando BP, Vestergaard LS, Kitua AY, Lemnge MM, Theander TG, Lusingu JPA. A progressive declining in the burden of malaria in north-eastern Tanzania. Malar J. 2010;9:216.
41. Naidoo I, Roper C. Following the path of most resistance: Dhps K540E dispersal in African Plasmodium falciparum. Trends Parasitol. 2010;26:447-56.
42. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci USA. 2009;106:9027-32.
43. Ringsted FM, Massawe IS, Lemnge MM, Bygbjerg IC. Saleability of anti-malarials in private drug shops in Muheza, Tanzania: A baseline study in an era of assumed artemisinin combination therapy (ACT). Malar J. 2011;10:238.
44. Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet. 2001;358:1066-7.
45. Khalil I, Rønn AM, Alifrangis M, Gabar HA, Satti GMH, Bygbjerg IC, et al. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. Am J Trop Med Hyg. 2003;68:586-9.
46. Matondo SI, Temba GS, Kavishe AA, Kauki JS, Kalinga A, van Zwetselaar M, et al. High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: A cross sectional survey of six regions in Tanzania. Malar J. 2014;13:152.
47. Raman J, Little F, Roper C, Kleinschmidt I, Cassam Y, Maharaj R, et al. Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. Am J Trop Med Hyg. 2010;82:788-94.
48. Alker AP, Mwapasa V, Purfield A, Rogerson SJ, Molyneux ME, Kamwendo DD, et al. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre. Malawi. Antimicrob Agents Chemother. 2005;49:3919-21.
49. Hastings MD, Bates SJ, Blackstone EA, Monks SM, Mutabingwa TK, Sibley CH. Highly pyrimethamine-resistant alleles of dihydrofolate reductase in isolates of Plasmodium falciparum from Tanzania. Trans R Soc Trop Med Hyg. 2002;96:674-6.
50. Malisa AL, Pearce RJ, Mutayoba BM, Abdullah S, Mshinda H, Kachur PS, et al. The evolution of pyrimethamine resistant dhfr in Plasmodium falciparum of south-eastern Tanzania: Comparing selection under SP alone vs SP + artesunate combination. Malar J. 2011;10:317.
51. Nsimba B, Jafari-Guemouri S, Malonga DA, Mouata AM, Kiori J, Louya F, et al. Epidemiology of drug-resistant malaria in Republic of Congo: Using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use. Trop Med Int Health. 2005;10:1030-7.
52. Mombo-Ngoma G, Oyakhirome S, Ord R, Gabor JJ, Greutélaers KC, Profanter K, et al. High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children. Malar J. 2011;10:123.